This site is intended for U.S. animal healthcare professionals
CYTOPOINT® safety information
CYTOPOINT® safety information
CYTOPOINT is a safe choice for virtually every dog with chronic canine atopic dermatitis
No known drug interactions—safe in combination with other medications, including1:
APOQUEL® (oclacitinib tablet), corticosteroids, cyclosporine and antihistamines
Treatments such as parasiticides, antibiotics, antifungals, vaccines, NSAIDs and allergen-specific immunotherapy
Targeted mechanism of action may help minimize side effects and avoid unwanted effects on immune function1
Does not burden the liver or kidneys
CYTOPOINT functions like naturally occurring antibodies and is eliminated via normal protein degradation pathways in the same way, which does not involve the liver or kidneys
CYTOPOINT was shown to be safe when administered to laboratory Beagles at up to 5 times the label dose (10 mg/kg) monthly for 7 months. No treatment effects on clinical observations or clinical pathology were identified
Ongoing safety monitoring
Ongoing pharmacovigilance monitoring, beginning in July 2015, continues to show a safety profile similar to that seen in clinical trials
Print
